Discussing the use of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.

Executed on:Jul 26, 2024 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: New Mexico Cancer CenterMedical Director of Radiation Oncology at the New Mexico Cancer Center & Assistant Professor of Medicine and the University of New Mexico.
Treats 7 patients per month with mCRPC and has 6 patients receiving Pluvicto every month.
Research and clinical interest in radiation oncology.

Interview Goal

On this call we will be speaking with a radiation oncologist to discuss the standard of care and the use of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.